全文获取类型
| 收费全文 | 4349篇 |
| 免费 | 496篇 |
| 国内免费 | 51篇 |
专业分类
| 耳鼻咽喉 | 48篇 |
| 儿科学 | 97篇 |
| 妇产科学 | 82篇 |
| 基础医学 | 349篇 |
| 口腔科学 | 87篇 |
| 临床医学 | 897篇 |
| 内科学 | 500篇 |
| 皮肤病学 | 51篇 |
| 神经病学 | 315篇 |
| 特种医学 | 153篇 |
| 外科学 | 610篇 |
| 综合类 | 354篇 |
| 一般理论 | 5篇 |
| 预防医学 | 951篇 |
| 眼科学 | 56篇 |
| 药学 | 196篇 |
| 4篇 | |
| 中国医学 | 64篇 |
| 肿瘤学 | 77篇 |
出版年
| 2024年 | 38篇 |
| 2023年 | 107篇 |
| 2022年 | 119篇 |
| 2021年 | 258篇 |
| 2020年 | 298篇 |
| 2019年 | 207篇 |
| 2018年 | 204篇 |
| 2017年 | 209篇 |
| 2016年 | 202篇 |
| 2015年 | 175篇 |
| 2014年 | 253篇 |
| 2013年 | 385篇 |
| 2012年 | 215篇 |
| 2011年 | 226篇 |
| 2010年 | 180篇 |
| 2009年 | 174篇 |
| 2008年 | 191篇 |
| 2007年 | 148篇 |
| 2006年 | 142篇 |
| 2005年 | 130篇 |
| 2004年 | 120篇 |
| 2003年 | 96篇 |
| 2002年 | 83篇 |
| 2001年 | 72篇 |
| 2000年 | 64篇 |
| 1999年 | 55篇 |
| 1998年 | 69篇 |
| 1997年 | 40篇 |
| 1996年 | 38篇 |
| 1995年 | 46篇 |
| 1994年 | 47篇 |
| 1993年 | 29篇 |
| 1992年 | 22篇 |
| 1991年 | 24篇 |
| 1990年 | 26篇 |
| 1989年 | 23篇 |
| 1988年 | 26篇 |
| 1987年 | 27篇 |
| 1986年 | 12篇 |
| 1985年 | 25篇 |
| 1984年 | 15篇 |
| 1983年 | 10篇 |
| 1982年 | 13篇 |
| 1981年 | 9篇 |
| 1980年 | 10篇 |
| 1979年 | 6篇 |
| 1978年 | 7篇 |
| 1977年 | 4篇 |
| 1976年 | 3篇 |
| 1973年 | 4篇 |
排序方式： 共有4896条查询结果，搜索用时 15 毫秒
991.
992.
Nazik Yalniz;Emine Şenyuva;Ümran Görügen; 《International nursing review》2024,71(4):1100-1112
To determine the professional values of graduates of master's and doctoral programs in nursing and their views on the contribution of postgraduate education to their professional values. 相似文献
993.
Marika Skyttä RN Anna-Maija Pietilä PhD Minna Stolt PhD Mari Kangasniemi PhD 《Scandinavian journal of caring sciences》2023,37(4):884-896
Personal health-related resources are essential for women with breast cancer, as these help them to maintain their own health and well-being during different phases of their illness. The purpose of this integrative review was to identify, describe and synthetise what personal health-related resources have already been identified for this patient group. We carried out an integrative review to find papers that focused on personal health-related resources for women with breast cancer aged 18–64 years. The search covered 1 January 2005 to 31 May 2021 and was carried out using the CINAHL, PubMed, PsycINFO, Web of Science and Cochrane Library databases. It was limited to peer-reviewed scientific papers with abstracts published in English and 23 papers met the inclusion criteria. The data were analysed using content analysis. Personal health-related resources for women with breast cancer consisted of three different, but inherently interconnected, categories of personal strengths, person-centred cancer care and social support from and involvement in their cultural community. Personal health-related resources for women with breast cancer were multifaceted. Women need nursing support to identify and use these resources and future studies are needed to strengthen how they are measured. 相似文献
994.
995.
Spontaneous hemopneumothorax is potentially fatal and can mimic spontaneous pneumothorax when changes in vital signs and bloody discharge from the chest tube are absent. Attenuation values at computed tomography may help detect this condition. 相似文献
996.
杜仲（Eucommia ulmoides）,又称胶木,为杜仲科杜仲属植物,在我国已有超过两千年的药用历史。杜仲通常使用其干燥的树皮和叶子入药。由于其在临床应用中的较高安全性,杜仲叶已在2019年通过食用安全性评价正式列为药食同源物质,成为食品和保健品开发的有力资源。根据中医理论,杜仲具有补肝肾、强筋骨、安胎等功效。现代研究表明,杜仲的不同部位,如皮、叶、花和种子等,含有类似的化学成分,主要包括苯丙素类、萜类、黄酮类、酚酸类、甾体和多糖类等物质。杜仲因其丰富的成分,具有降血压、降血脂、降血糖、预防骨质疏松、抗肿瘤、抗菌抗病毒、抗炎、抗氧化、肝保护等多种药理作用,因此具有开发多样化药食同源产品的潜力。该文对杜仲不同部位的化学成分、药理作用及代表性的药食同源产品进行了系统整理,旨在为杜仲及其活性成分的临床应用及药食同源产品的开发利用提供理论参考。这将有助于深入了解杜仲的药用特性,并为进一步探索其在健康领域的应用提供指导。作为一种传统药食同源植物,杜仲将在未来的研究中引起更多关注,并有望为人们的健康作出更多贡献。 相似文献
997.
《Value in health》2023,26(5):760-767
ObjectivesThe European Organisation for Research and Treatment of Cancer Quality of Life Utility-Core 10 Dimensions (EORTC QLU-C10D) is a cancer-specific preference-based measure, providing health utilities for use in economic evaluations derived from the widely used health-related quality of life measure, EORTC QLQ-C30. Several EORTC QLU-C10D country-specific value sets are available. This article aimed to provide EORTC QLU-C10D general population utility norms for Canada, France, Germany, Italy, Poland, and the United Kingdom, to aid interpretability of obtained utilities in these countries.MethodsData were collected in aforementioned countries via a quota-sampled, cross-sectional online survey (n = 100/age-sex group; N = approximately 1000/country). Participants were asked to complete the EORTC QLQ-C30 and provide sociodemographic data. Country-specific utility norms were calculated using the respective country tariff on the country’s EORTC QLQ-C30 data after weighting to achieve population representativeness for age and sex. Norm values are provided as means (SDs) by country, age, and sex groups. Tukey’s multiple comparison test investigated mean differences among countries. The impact of country, age, and sex on utility values was investigated with a multiple linear regression model.ResultsCountry-specific mean utilities range from 0.724 (United Kingdom) to 0.843 (Italy). Country-, sex-, and age-specific mean utilities range from 0.664 for 30- to 39-year-old male Canadians to 0.899 for > 70-year-old male Italians. Utilities were lower in females in 4 of 6 countries, and the impact of age differed among countries. Independent of the impact of age and sex, between-country differences were found (P ≤ .05).ConclusionResults showed a varying impact of age and sex on EORTC QLU-C10D utilities and significant between-country differences. Using national utility norms and utility decrements is recommended. 相似文献
998.
Jennifer E. Lutomski PhD Linda Rainey PhD Milou de Jong MSc Peggy Manders PhD Mireille J. M. Broeders PhD 《Health expectations》2023,26(3):1308-1317
Introduction
Understanding participants' concerns and information needs regarding broadened consent is crucial to ensure transparency and participant autonomy. Our study qualitatively examined these issues in women participating in the Personalized RISk-based MAmmascreening study (PRISMA). The original PRISMA informed consent was project-specific (i.e., breast cancer research), limiting the scope of secondary research. We explored participants' needs for broadened consent to preserve informed decision-making while maximising the potential re-use of data.Methods
Focus groups (FGs) were performed following a semistructured discussion guide. Two independent researchers analysed the data thematically using an inductive approach.Findings
Twenty-three asymptomatic women and 13 women diagnosed with breast cancer were randomly divided into six FGs. Four superordinate themes were identified: (1) Normalization, (2) Attitude towards the pharmaceutical industry, (3) Privacy and (4) Knowledge. Our participants viewed data sharing as an important conduit for advancing medical science. Perceived integrity was more often attributed to noncommercial than commercial parties, with a marked mistrust towards the pharmaceutical industry. Most requested information needs related to data protection. Participants' ideal consent process would confer a range of options; for example, they would be able to choose with whom data can be shared, whether data will be de-identified or anonymous, the expiration date of their consent and how, if requested, general and personal study results would be disclosed.Conclusion
Our participants expressed clear information needs and a strong desire to be actively engaged in future data sharing decisions. Given that many researchers collaborate with commercial parties, building public confidence in these institutions would be beneficial. Illustrative examples addressing privacy concerns and clarifying difficult terms would aid consent decision-making. Although our participants displayed great altruism in sharing their data and accepted that broad consent would ultimately facilitate future research, broad consent did not reflect their ideal situation. Dynamic consent may be an option but warrants further feasibility research.Patient and Public Contribution
Women were recruited from the general breast cancer screening population. Their perceptions and information needs, as reported in this study, will not only inform broadened consent for PRISMA but ideally guide other consent templates and decisions regarding consent processes. 相似文献999.
《Journal of infection and chemotherapy》2022,28(8):1193-1197
Bedaquiline is a new ATP synthesis inhibitor developed as an anti-tuberculosis agent. It has resistance-associated variants (RAV), regardless of preceding bedaquiline exposure. Herein, we describe the case of a patient with multidrug-resistant tuberculosis (MDR-TB) who had no history of bedaquiline therapy but presented a relatively high minimum inhibitory concentration (MIC) of bedaquiline (1 μg/mL). Whole genome sequencing revealed a mutation in the resistance-associated gene Rv0678. The patient was first treated with a five-drug regimen (bedaquiline, delamanid, levofloxacin, cycloserine, and amikacin), which induced negative sputum culture conversion. Despite the successful treatment outcome, several questions remain regarding the efficacy of bedaquiline in this patient. Bedaquiline is an indispensable drug for MDR-TB treatment, but its clinical efficiency in the presence of Rv0678 mutations remains unclear. Therefore, evaluating the MIC of bedaquiline even in patients without a history of bedaquiline use is important for therapeutic regimen selection and may emphasize the importance of therapeutic drug monitoring in cases of bedaquiline RAV. 相似文献
1000.
《Journal of the American College of Surgeons》2020,230(6):1064-1073
- Download : Download high-res image (284KB)
- Download : Download full-size image